Brentuximab Vedotin,developed by Seattle Genetics, is the leading product.
R&D activities and technologies used along with the pipeline molecules in development.
Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
Information related to collaborations, in-licensing and out-licensing deals.
DelveInsights, Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the in-depth analysis of Antibody Drug Conjugate Landscape across the globe. Therefore the report on Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provide information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.
DelveInsight is offering the Report at a price of USD 2950 as a single user license, USD 5900 as a site license and USD 8850 as a Global/Enterprise License.
For more information on Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report, email at info@delveInsight.com
About Us:
DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.
